12 Mar 2014, BioSpectrum Bureau , BioSpectrum
Singapore: Eisai, US, subsidiary of Tokyo-based Eisai, has appointed Mr Yuji Matsue as chairman and chief executive officer and Mr Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr Matsue and Ms Procida succeed the present president and CEO Mr Lonnel Coats. He will be retiring from Eisai in June 2014 after 18 years.
Mr Matsue will be responsible for the strategic direction of the Americas region and Ms Procida will have full operating responsibility for the US business. Together they also will provide regional management support and oversight to all of Eisai's operating companies and units in the Americas.
Mr Haruo Naito, president and CEO, Eisai, said that, "Yuji and Shaji bring significant industry experience and expertise to their new roles within Eisai. Their leadership will be instrumental in taking Eisai to the next level as we work to broaden access to many of Eisai's products across the Americas Region and advance our human health care mission."
Mr Naito further said, "We are grateful to Lonnel Coats for the outstanding leadership he has displayed during his 18-year tenure with Eisai. He has played an integral role in shaping Eisai's business strategy and operations, positioning us for continued success. On behalf of everyone at Eisai, I express my deep appreciation to Lonnel for his many contributions."
Mr Coats said that, "I thank Mr Naito for the privilege of leading Eisai's Americas business and advancing our company's human healthcare mission to serve patients and their families. After 10 years at the helm of Eisai, US, I am immensely proud to turn over the leadership of our business to my colleagues, Yuji Matsue and Shaji Procida. They are highly skilled executives with deep knowledge of our company, our products and our partners, and are dedicated to our patient-centered approach to running our business."